Additional file 2: Figure S1. of Modest heterologous protection after Plasmodium falciparum sporozoite immunization: a double-blind randomized controlled clinical trial

First-wave parasitemia after challenge. Parasitemia on day 7 post-challenge in immunized (open circles) and control (closed circles) volunteers. The line and error bars show the geometric mean and 95% CI interval. Figure S2. Inhibition of in vitro homologous and heterologous intra-hepatic sporozoite development in primary human hepatocytes by mAb 2A10. P. falciparum NF54 (blue), NF135.C10 (orange) and NF166.C8 (green) sporozoites in the presence of 10% heat-inactivated naive human control serum were pre-incubated with 3-fold serial dilutions of the 2A10 monoclonal antibody (0.027–20 μg/mL), targeting the repeat region of the circumsporozoite protein (CSP), and added to primary human hepatocyte cultures. Six days post-infection, the number of P. falciparum-infected hepatocytes was assessed as described in Additional file 1: S4 and S5. Figure S3. Amino acid changes in CSP. Table S1. Whole-genome sequencing statistics. Table S2. Mosquito salivary gland infectivity and sporozoite load of the three clones. Mean mosquito salivary gland infectivity and sporozoite load determined 1 day prior to challenge infection by dissecting a sample of 10 mosquitoes per strain. (DOCX 427 kb

Protein microarray serological data

Background corrected and normalised microarray median florescence intensity data, for all individuals in the study (n=648). Data from IVTT protein targets are presented along with control targets in tab 1 and 2 (n=762). Data from the gametocyte IVTT protein targets only are presented in tab 3 (n=528)

Metadata for the protein micro-array serological analysis

Metadata for the protein microarray serological analysis. Full description of the variables provided is in tab 2 (key)